Conduit Pharma

Conduit is a clinical-stage specialty biopharmaceutical company with a development pipeline that includes glucokinase inhibitors for multiple Phase II autoimmune diseases, including uveitis, Hashimoto's thyroiditis, preterm birth, and kidney transplantation. Conduit's development pipeline also features a potent, irreversible human myeloperoxidase (MPO) inhibitor with potential for treating idiopathic male infertility. Following successful clinical trials, Conduit licenses these assets to large pharmaceutical companies, typically in exchange for milestone payments, while retaining royalty income streams for the duration of the asset patents. The company will utilize its royalty income streams to develop its portfolio, balancing forward revenue stream sales with debt or equity financing.